Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

Inclusion Criteria: 1. PD patients between the ages of 30-85; 2. Patients with Parkinson's disease dyskinesia, and UPDRS 4.2 score ≥ 2 points; 3. The patient diary shows that there are at least two opening periods between 9 am and 4 pm every day, and the dyskinesia appears in the opening period, each time lasting more than half an hour; 4. The treatment plan for anti-Parkinson's disease is stable and not adjusted within 30 days before enrollment; 5. Levodopa is administered at least three times a day. Exclusion Criteria: 1. PD patients with biphasic, dystonia, closure, myoclonus, but no dyskinesia; 2. pregnant and lactating women; 3. Taking other Chinese medicines against Parkinson's disease 2 weeks before enrollment; 4. Impaired cognitive function (according to pre-entry MMSE score): secondary education level: MMSE \<24 points; primary education level \<20 points; illiterate \<17 points; 5. Psychiatric symptoms associated with anti-Parkinson's disease drugs 6. accompanied by a history of mental illness; 7. impaired liver and kidney function; 8. accompanied by severe other systemic diseases; 9. Amantadine treatment has been received within the first 30 days of enrollment; 10. History of medication with apomorphine or dopamine receptor antagonists; 11. Previously taking amantadine, unable to tolerate; 12. Allergic to the amantadine, memantine, and traditional Chinese medicine preparations or serious adverse reactions; 13. Before the enrollment, the EKG showed obvious abnormalities and required clinical intervention. 14. has received PD-related brain surgery; 15. Patients who are participating in other clinical studies or have participated in other clinical studies within the previous 30 days; 16. Patients who are unable to follow up with follow-up.